Maureen Cooper
Hematology & Oncology · Alamosa, CONPI 1356310890
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Amgen accounts for 77.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $41,525 and has fallen 70.4% since, to $12,292 in 2023.
Across 217 payments — averaging $391.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$66K
- Johnson & Johnson$5K
- Incyte Corporation$5K
- GSK$2K
- Array Biopharma Inc$2K
- Novartis$2K
- plus $3K from 24 others
Across 3 payments — averaging $1816.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$5K
What the payments were for
- Consulting fees$11,53014%
- Speaking & faculty fees$50,39059%
- Travel & lodging$18,14021%
- Food & beverage$3,2044%
- Education$1730%
- Gifts$250%
- Other$1,5152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 104 | $65,862 |
| Johnson & Johnson | 15 | $5,033 |
| Incyte Corporation | 10 | $4,638 |
| GSK | 4 | $2,390 |
| Array Biopharma Inc | 2 | $1,902 |
| Novartis | 37 | $1,779 |
| Jazz Pharmaceuticals Inc. | 3 | $1,532 |
| Genentech USA, Inc. | 3 | $999 |
| Daiichi Sankyo Inc. | 3 | $160 |
| Janssen Scientific Affairs, LLC | 2 | $103 |
| Seagen Inc. | 3 | $62 |
| Merck | 4 | $60 |
| Bayer | 3 | $54 |
| Gilead | 3 | $45 |
| Macrogenics, Inc. | 2 | $40 |
| Clovis Oncology, Inc. | 3 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Pfizer | 2 | $26 |
| The Binding Site Inc. | 1 | $25 |
| Karyopharm Therapeutics Inc. | 2 | $25 |
| Taiho Oncology, Inc. | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $20 |
| Organon | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,977 in reported general payments places this provider in the 85th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Alamosa
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.